Advancing HER2+
Breast-Cancer Therapy
Trastuzumab and hyaluronidase-oysk (Herceptin Hylecta) was approved by the FDA to be used in subcutaneous form for the treatment of HER2-positive breast cancer based on two large, randomized trials. The recommended dose is 600 mg/10,000 units subcutaneously over 2 to 5 minutes once every 3 weeks, with major side effects listed as fatigue, diarrhea, arthralgia, and upper respiratory tract infections. Read more.

First Systemic Therapy for
Giant Cell Tumor
Pexidartinib was approved on August 2, 2019 by the FDA as the first systematic therapy for a rare tumor type—symptomatic tenosynovial giant cell tumor. Pexidartinib showed an improvement in overall response rate in a large multicenter trial. Pexidartinib is only available through a risk-evaluation and mitigation strategy program due to liver toxicity. Read more.